Dr. Bing Tian received his Ph.D. degree in 1999 from UTMB. He is an expert of cellular and molecular biology/virology, mucosal innate signaling, small-animal models, and drug development. Also, he is a pharmacologist with formal pharmacology training.
He has been working on the virus-, allergen-, and cytokine-induced innate immune response in the airway epithelium and signaling pathways of other chronic diseases for over 20 years, and has made substantial contributions to this field, with over
60 publications, an H-index of 28 and 2800 citations as well as 4 patents. He has focused on the following research fields:
- The Nuclear factor-κB (NFκB) signaling pathway in chronic diseases.
- Systems Biology of Airway epithelial–mesenchymal transition (EMT).
- Bromodomain-containing protein 4 (BRD4) Inhibitors and Chronic Airway inflammation-induced Remodeling/Pulmonary Fibrosis. /li>
- Viral and allergen infection-related pulmonary inflammation and disease.
- Novel therapeutics of inflammatory bowel diseases (IBD).
More recently, he has focused his research on the molecular mechanisms of Chronic obstructive pulmonary disease (COPD) and asthma-associated airway remodeling/lung fibrosis. Using multiple experimental approaches, he has delineated the central role of
the NFκB-BRD4 signaling pathway in the chronic airway inflammation-induced mesenchymal transition of epithelial cells and have linked this signaling pathway with airway remodeling/pulmonary fibrosis in vivo. Also, he has identified
and developed highly specific BRD4 inhibitors (BRD4i) which significantly revered the viral infection and allergen induced airway inflammation/lung fibrosis. Furthermore, he has developed nanoparticle-encapsulated BRD4 inhibitors as novel nano-medications
for treatment of IBD patients.